Price Disclosure Reductions for 2019 April Cycle

Page last updated: 14 December 2018

This summary only includes medicines taking a price disclosure reduction on 1 April 2019. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2019 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs in late January 2019.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2018 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2018 will also take the reduction on 1 April 2019 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on 21 December 2018.

Indicative prices for 1 April 2019 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2019. Subscribe to PBS News to receive notice when they become available.

Final prices for 1 April 2019 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from early March 2019.

Excel version of 2019 April Cycle Outcomes Summary - (Excel 46 KB)

2019 April Cycle Outcomes Summary
Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)	Legal Instrument MoA	Legal Instrument Form	Average AEMP ($)	WAPD (%) across a drug/MoA	WADP - potential April '19 PBS Price (AEMP) ($) per pharmaceutical item	October '18 AEMP ($)	Percentage difference between October '18 and April '19 PBS prices (AEMP) (%) per pharmaceutical item	Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item No originator brand determined Does not meet 30 month clock	Applicable Unadjusted Price Reduction 10% or 30%
	Legal Instrument MoA	Legal Instrument Form	[Average AEMP minus WAPD = WADP]			[Difference between October '18 AEMP & WADP = % Difference]			Applicable Unadjusted Price Reduction 10% or 30%
Aripiprazole	Oral	Tablet 10 mg	88.33	15.69%	74.47	88.33	15.69%	OWAPD	10
Aripiprazole	Oral	Tablet 15 mg	125.35	15.69%	105.68	125.35	15.69%	OWAPD	10
Aripiprazole	Oral	Tablet 20 mg	152.58	15.69%	128.64	152.58	15.69%	OWAPD	10
Aripiprazole	Oral	Tablet 30 mg	185.93	15.69%	156.76	185.93	15.69%	OWAPD	10
Atomoxetine	Oral	Capsule 10 mg (as hydrochloride)	56.67	26.51%	41.65	56.67	26.50%	OWAPD	10
Atomoxetine	Oral	Capsule 100 mg (as hydrochloride)	73.67	26.51%	54.14	73.67	26.51%	OWAPD	10
Atomoxetine	Oral	Capsule 18 mg (as hydrochloride)	56.67	26.51%	41.65	56.67	26.50%	OWAPD	10
Atomoxetine	Oral	Capsule 25 mg (as hydrochloride)	56.67	26.51%	41.65	56.67	26.50%	OWAPD	10
Atomoxetine	Oral	Capsule 40 mg (as hydrochloride)	56.67	26.51%	41.65	56.67	26.50%	OWAPD	10
Atomoxetine	Oral	Capsule 60 mg (as hydrochloride)	56.67	26.51%	41.65	56.67	26.50%	OWAPD	10
Atomoxetine	Oral	Capsule 80 mg (as hydrochloride)	73.67	26.51%	54.14	73.67	26.51%	OWAPD	10
Azacitidine	Injection	Powder for injection 100 mg	317.31	31.41%	217.64	270.02	19.40%	OWAPD	10
Baclofen	Injection	Intrathecal injection 10 mg in 5 mL	124.63	10.71%	111.28	124.63	10.71%	OWAPD	10
Baclofen	Injection	Intrathecal injection 40 mg in 20 mL	498.40	10.71%	445.02	498.40	10.71%	OWAPD	10
Celecoxib	Oral	Capsule 100 mg	5.23	12.03%	4.60	5.23	12.05%	GWAPD	10
Celecoxib	Oral	Capsule 200 mg	5.23	12.03%	4.60	5.23	12.05%	GWAPD	10
Desvenlafaxine	Oral	Tablet (extended release) 100 mg (as succinate)	13.21	12.04%	11.62	13.21	12.04%	OWAPD	10
Desvenlafaxine	Oral	Tablet (extended release) 50 mg (as succinate)	10.76	12.04%	9.46	10.76	12.08%	OWAPD	10
Desvenlafaxine	Oral	Tablet (modified release) 100 mg	13.21	12.04%	11.62	13.21	12.04%	OWAPD	10
Desvenlafaxine	Oral	Tablet (modified release) 100 mg (as benzoate)	13.21	12.04%	11.62	13.21	12.04%	OWAPD	10
Desvenlafaxine	Oral	Tablet (modified release) 50 mg	10.76	12.04%	9.46	10.76	12.08%	OWAPD	10
Desvenlafaxine	Oral	Tablet (modified release) 50 mg (as benzoate)	10.76	12.04%	9.46	10.76	12.08%	OWAPD	10
Entecavir	Oral	Tablet 0.5 mg (as monohydrate)	234.64	28.04%	168.85	210.81	19.90%	OWAPD	10
Entecavir	Oral	Tablet 1 mg (as monohydrate)	381.59	28.04%	274.59	342.84	19.91%	OWAPD	10
Epirubicin	Injection/Intravesical	Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL	58.22	44.88%	32.09	58.22	44.88%	OWAPD	30
Epirubicin	Injection/Intravesical	Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL	116.44	44.88%	64.18	116.44	44.88%	OWAPD	30
Epirubicin	Injection/Intravesical	Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL	29.11	44.88%	16.05	29.11	44.86%	OWAPD	30
Epoprostenol*	Injection	Powder for I.V. infusion 1.5 mg (as sodium)	66.55	10.85%	59.33	66.55	10.85%	OWAPD	10
Epoprostenol*	Injection	Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL	66.55	10.85%	59.33	66.55	10.85%	OWAPD	10
Epoprostenol*	Injection	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL	33.28	10.85%	29.67	33.28	10.85%	OWAPD	10
Filgrastim	Injection	Injection 120 micrograms in 0.2 mL single use pre-filled syringe (Nivestim)	182.87	32.28%	123.84	182.87	32.28%	OWAPD	30
Filgrastim	Injection	Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen)	457.18	32.28%	309.60	457.18	32.28%	OWAPD	30
Filgrastim	Injection	Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)	457.18	32.28%	309.60	457.18	32.28%	OWAPD	30
Filgrastim	Injection	Injection 300 micrograms in 0.5 mL single use pre-filled syringe (TevaGrastim)	457.18	32.28%	309.60	457.18	32.28%	OWAPD	30
Filgrastim	Injection	Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Zarzio)	228.59	32.28%	154.80	228.59	32.28%	OWAPD	30
Filgrastim	Injection	Injection 300 micrograms in 1 mL	457.18	32.28%	309.60	457.18	32.28%	OWAPD	30
Filgrastim	Injection	Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen)	732.89	32.28%	496.31	732.89	32.28%	OWAPD	30
Filgrastim	Injection	Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)	732.89	32.28%	496.31	732.89	32.28%	OWAPD	30
Filgrastim	Injection	Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Zarzio)	366.44	32.28%	248.15	366.44	32.28%	OWAPD	30
Filgrastim	Injection	Injection 480 micrograms in 0.8 mL single use pre-filled syringe (TevaGrastim)	732.89	32.28%	496.31	732.89	32.28%	OWAPD	30
Filgrastim	Injection	Injection 480 micrograms in 1.6 mL	732.89	32.28%	496.31	732.89	32.28%	OWAPD	30
Ganciclovir	Injection	Powder for I.V. infusion 500 mg (as sodium)	223.44	10.19%	200.67	223.44	10.19%	OWAPD	10
Idarubicin	Injection	Solution for I.V. injection containing idarubicin hydrochloride 10 mg in 10 mL	70.47	37.50%	44.04	70.47	37.51%	GWAPD	30
Idarubicin	Injection	Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL	36.45	37.50%	22.78	36.45	37.50%	GWAPD	30
Irinotecan	Injection	I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL	13.42	39.56%	8.11	13.42	39.57%	OWAPD	30
Irinotecan	Injection	I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL	5.37	39.56%	3.25	5.37	39.48%	OWAPD	30
Irinotecan	Injection	I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL	67.12	39.56%	40.57	67.12	39.56%	OWAPD	30
Naloxone	Injection	Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe	43.12	20.32%	34.36	43.12	20.32%	OWAPD	10
Naloxone	Injection	Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule	48.89	20.32%	38.96	48.89	20.31%	OWAPD	10
Olmesartan	Oral	Tablet containing olmesartan medoxomil 20 mg	5.63	22.85%	4.34	5.63	22.91%	OWAPD	10
Olmesartan	Oral	Tablet containing olmesartan medoxomil 40 mg	11.94	22.85%	9.21	11.94	22.86%	OWAPD	10
Olmesartan with hydrochlorothiazide	Oral	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	7.07	18.67%	5.75	7.07	18.67%	OWAPD	10
Olmesartan with hydrochlorothiazide	Oral	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	13.38	18.67%	10.88	13.38	18.68%	OWAPD	10
Olmesartan with hydrochlorothiazide	Oral	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	14.81	18.67%	12.04	14.81	18.70%	OWAPD	10
Pemetrexed	Injection	Powder for I.V. infusion 1 g (as disodium)	131.35	41.66%	76.63	92.43	17.09%	OWAPD	10
Pemetrexed	Injection	Powder for I.V. infusion 100 mg (as disodium)	13.14	41.66%	7.67	9.24	16.99%	OWAPD	10
Pemetrexed	Injection	Powder for I.V. infusion 500 mg (as disodium)	65.67	41.66%	38.31	46.21	17.10%	OWAPD	10
Tenofovir with emtricitabine	Oral	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	220.34	34.82%	143.62	220.34	34.82%	OWAPD	10
Tenofovir with emtricitabine	Oral	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	220.34	34.82%	143.62	220.34	34.82%	OWAPD	10
Tenofovir with emtricitabine	Oral	Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg	220.34	34.82%	143.62	220.34	34.82%	OWAPD	10
Valganciclovir	Oral	Tablet 450 mg (as hydrochloride)	1792.15	41.92%	1040.88	1506.30	30.90%	OWAPD	10
Voriconazole	Oral	Tablet 200 mg	1276.15	24.97%	957.50	1276.15	24.97%	OWAPD	10
Voriconazole	Oral	Tablet 50 mg	319.04	24.97%	239.38	319.04	24.97%	OWAPD	10

Price Disclosure Reductions for 2019 April Cycle

Flow-on Reductions for F2 Combination Items

Legal Determination & Next Steps

Department of Health, Disability and Ageing

Pharmaceutical Benefits Scheme

PBS Information

Browse the PBS

For Health Professionals

For Industry